NPPB and pulmonary arterial hypertension: Adding oral treprostinil to background monotherapy significantly reduced the risk of clinical worsening in PAH patients, with improvements in NT-proBNP, functional class, and dyspnea. Safety profile was consistent with prostacyclin-class therapy (high rates of headache, diarrhea).